# Durvalumab

Source: https://nuclide.cc/drugs/durvalumab/  
Nuclide record `durvalumab` (Agent). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.

## Summary

PACIFIC (unresectable stage III NSCLC), ADRIATIC (limited-stage SCLC, 2024), TOPAZ-1 (biliary tract), HIMALAYA (HCC with tremelimumab), NIAGARA (perioperative muscle-invasive bladder cancer, 2025), MATTERHORN (perioperative gastric, 2025), and Q2 2026 high-risk non-muscle-invasive bladder cancer with BCG (POTOMAC). Partner of Dato-DXd in TROPION-Breast05.

## Fields

- Kind: Agent
- Status: approved
- Last checked: 2026-09-04
- Brand: Imfinzi
- Modality: Monoclonal antibody (anti-PD-L1)
- Mechanism: Human IgG1 anti-PD-L1 with reduced Fc effector function.
- Approvals: US 2017: Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021); US 2018: Unresectable stage III NSCLC after chemoradiation; US 2026: High-risk NMIBC with BCG
- Dosing: IV infusion; 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks (≥30 kg); up to 12 months after chemoradiation in stage III NSCLC

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Durvalumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab

## Connected records

- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Intermediate hepatocellular carcinoma (BCLC B)](https://nuclide.cc/indications/hcc-intermediate/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)
- companies: [AstraZeneca](https://nuclide.cc/companies/astrazeneca/)
- trials: [A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat](https://nuclide.cc/trials/nct06040099/), [TheraSphere With Durvalumab and Tremelimumab for HCC](https://nuclide.cc/trials/nct05063565/)
- pairings: [Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/)

---
JSON: https://nuclide.cc/api/v1/entities/durvalumab.json